Page 31«..1020..30313233..4050..»

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Posted: September 2, 2024 at 2:53 am

STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024.

Continue reading here:
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Posted in Global News Feed | Comments Off on Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted: September 2, 2024 at 2:53 am

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart.

Read the rest here:
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted in Global News Feed | Comments Off on Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Disc Medicine to Participate in Upcoming Investor Conferences

Posted: September 2, 2024 at 2:53 am

WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

Here is the original post:
Disc Medicine to Participate in Upcoming Investor Conferences

Posted in Global News Feed | Comments Off on Disc Medicine to Participate in Upcoming Investor Conferences

Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference…

Posted: September 2, 2024 at 2:53 am

PALO ALTO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced oral, poster presentations, and symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek conference in Las Vegas, NV on September 3-5, 2024.

See more here:
Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference...

Posted in Global News Feed | Comments Off on Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference…

Nymox Announces Filing of Annual Report

Posted: September 2, 2024 at 2:53 am

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to report that it filed its Annual Report with the Security and Exchange Commission (SEC) on August 29, 2024.

See the original post:
Nymox Announces Filing of Annual Report

Posted in Global News Feed | Comments Off on Nymox Announces Filing of Annual Report

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label…

Posted: September 2, 2024 at 2:53 am

- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) at Month 1 of the OLE (n=21) and mean of 3.4mg/dL increase in serum TTR at Month 6 of the OLE (n=18)

See the rest here:
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label...

Posted in Global News Feed | Comments Off on BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label…

Total number of shares and voting rights in Zealand Pharma on August 30, 2024

Posted: September 2, 2024 at 2:53 am

Company announcement – No. 42 / 2024

Go here to read the rest:
Total number of shares and voting rights in Zealand Pharma on August 30, 2024

Posted in Global News Feed | Comments Off on Total number of shares and voting rights in Zealand Pharma on August 30, 2024

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with…

Posted: September 2, 2024 at 2:53 am

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety signals observed at interim analysis- Primary endpoint of progression free survival projected to be reached in the first half of 2025

Link:
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with...

Posted in Global News Feed | Comments Off on IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with…

Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update

Posted: September 2, 2024 at 2:53 am

All dollar amounts reflected in Canadian dollars unless otherwise stated.

See original here:
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update

Posted in Global News Feed | Comments Off on Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update

Receipt of Nasdaq Delisting Determination – Plans to Appeal

Posted: September 2, 2024 at 2:53 am

August 30, 2024

Go here to read the rest:
Receipt of Nasdaq Delisting Determination - Plans to Appeal

Posted in Global News Feed | Comments Off on Receipt of Nasdaq Delisting Determination – Plans to Appeal

Page 31«..1020..30313233..4050..»